‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
LifeMine Therapeutics secured substantial new funding from high-profile investors including Bill Gates and Jeff Bezos for its drug discovery platform.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 3.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
Source diversity sample: The Business Journals · marketscreener.com · Endpoints News · STAT · Fierce Biotech.
How this dossier is built: methodology · AI policy · corrections.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
What happened
Conflicting reports have emerged regarding the total capital secured by LifeMine Therapeutics, with some sources citing a $188 million Series E round while others report a total raise of $263 million. The biotech company, led by Greg Verdine, is focusing these resources on the development of a safer immunosuppressant. Fierce Biotech and Endpoints News note that the platform’s potential was a key driver in winning over major investors.
According to coverage from The Business Journals, funds associated with Bill Gates and Jeff Bezos are among the financial backers participating in the investment. STAT reports that the executive leadership is currently experiencing a period of operational success. LifeMine Therapeutics now holds the additional capital to proceed with its research objectives.
Details concerning the specific timeline for the clinical advancement of the immunosuppressant and the allocation of the differing funding amounts remain unspecified by available information.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Sources (5)
- LifeMine Therapeutics raises $263M; investors include Bezos, Gates funds The Business Journals · 8h ago
- LifeMine Therapeutics, Inc. announced that it has received $188 million in funding from a group of investors marketscreener.com · 8h ago
- Greg Verdine’s LifeMine raises $263M for safer immunosuppressant Endpoints News · 8h ago
- A scientist-turned-biotech executive is notching some wins, and enjoying it STAT · 8h ago
- ‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E Fierce Biotech · 8h ago
Questions people are asking
Who are the notable investors in LifeMine Therapeutics?
Investment funds associated with Bill Gates and Jeff Bezos are among the participants.
What is the primary focus of LifeMine Therapeutics' research?
The company is utilizing its platform to develop a safer immunosuppressant.
How much funding did the company raise?
Reported figures vary between $188 million and $263 million.
Topics
Related trends
Jeff Bezos Is World's Third-Richest Again—Overtaking Google’s Sergei Brin
Amazon's stock surge has propelled Jeff Bezos back into the top three of the world's richest people.
Adam O’Neal departs as Post Opinions editor after a year
The Washington Post's opinion section faces uncertainty as its editor departs after a year
FDA Panel Votes In Favor of Replimune’s Melanoma Treatment
An FDA advisory committee has voted 10-3 in favor of Replimune’s oncolytic immunotherapy for melanoma, marking a turning point for the twice-rejected treatment.
MapLight shares sink on mixed ph. 2 schizophrenia readout
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Argenx to Buy Forte Biosciences for $2.2 Billion
8 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Huge News for Rocket Lab Investors
Rocket Lab (RKLB) is drawing investor attention amid stock price volatility and its growing competition with industry giants like Elon Musk and Jeff Bezos.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.